ESMO 2024

4-year update of Riboclib in EBC - can we avoid chemo?

Hypofractionation in early breast cancer

Escalation, De-escalation and management of therapy:…

New updates from the innovative I-SPY program

Survival benefit reported with Pembro

Endocrine therapy in triple-positive premenopausal…

Registry data from France - no break in endocrine…

Survival data from WSG-TP-II

Physical exercise and oncological outcome

Overall survival advantage for Pembrolizumab in early…

Update on NATALEE in young patients

4-year landmark data

Ribociclib in younger patients

Physical exercise and oncological outcome

De-Escalation in the metastatic setting

TILs and overall survival in the shortHER trial

Brain imaging screening in MBC patients

Highlights of ESMO 2024

No benefit of Akt-inhibition in mTNBC

Akt-inhibition works with HR+ but not with mTNBC

PIK3CA is not a vaild pathway in triple-negative breast…

Keep the patients trained!

Brain imaging screening in MBC patients

Nuovi approcci per il trattamento dei pazienti 1L mTNBC

Punti salienti di ESMO 2024

TILs e sopravvivenza nello studio shortHER

New first choice treatment for patients with brain…

Efficacy of T-Dxd in patients with brain metastasis

HER3- DXd in the ICARUS Breast-01 study

High sensitivity testing as outcome predictor for T-DXD…

ctDNA data and clinical efficacy of SG

Endocrine-based therapy in combination with dual…

Her3-Dxd - new application area for ADCs

T-Dxd in BrainMets

Soon no chemotherapy for triplenegative mBC

Optimization treatment with ADCs in endocrine therapy

Study impression in HR+/HER2- mBC progressing after two…

Primary systematic treatment of active brain metastases

Outstanding efficacy of T-Dxd in CNS meastases

T-Dxd in patients with and without brain metastases

Impression d'étude dans le cancer du sein métastatique…

Optimization treatment with ADCs in endocrine therapy

Risultati primari dello studio DB-12

CTCs as surrogate markers for endocrine therapy

The importance of markers for patient management

Neoadjuvant vs. Perioperative

Perioperative IO Therapy - adjuvant necessary?

Durvalumab did not meet primary endpoint in CCTG BR.31…

ctDNA - a promising new biomarker in early lung cancer

Getting rid of it will save your life!

Negative adjuvant CPI trial

Significant CNS protection by osimertinib

BR31: The first negative adjuvant study in resected…

Should we move away from adjuvant immunotherapy?

BR31: La première étude d’immunothérapie adjuvante…

Durvalumab non ha raggiunto l'endpoint primario nello…

New 1st line treatment opportunities in advanced stage…

Pieces of evidence in the EGFR domain

MARIPOSA - lower rate of MET amplification and EGFR…

Adding anti-LAG-3 doesn't seem to being worth it

1st line encorafenib + binimetinib: combination is very…

Quality of life with Telisotuzumab in LUMINOSITY

NVL-655: a promising new ALK inhibitor

Early mechanisms of resistance from MARIPOSA

RELATIVITY-104: efficacy of anti immunotherapy

Optimizing the dose of immunotherapy

Promising signal for anti-TIGIT + anti-PD-1 with PD-L1…

The next generation of ROS inhibitors

Patterns of resistance in MARIPOSA trial

Survival Data with Amivantamab for EGFR Alteration

NVL-520 for ROS alteration - already best in class?

Half of the dose - same activity: provocative findings…

4th generation with ALK-alterations

Second interim analysis of MARIPOSA-2

The next generation of ALK inhibitors

Two sometimes may be better than one!

Bispecific antibodies better than ADCs?

NVALT: 1st attempt to reduce dose of pembrolizumab and…

CBNPC muté BRAF en 1ère ligne : encorafenib +…

Aggiungere l'anti-LAG-3 non sembra valerne la pena

Optimizing the dose of immunotherapy

Patterns of resistance in MARIPOSA trial

Quality of life with Telisotuzumab in LUMINOSITY

RELATIVITY-104: efficacy of anti immunotherapy

NVALT: Première tentative pour réduire la dose de…

2 a volte sono meglio di uno

Subset analysis from ADRIATIC

Response assessment in mesothelioma - can AI help?

Doublet therapy in prostate cancer: Practice changing…

Practice changing- Big Revival - Or just a Splish?…

Molecular analysis from PEACE-1

Upfronts in personal

Radium223 Prior to Docetaxel Improves Quality of Life…

New hormone therapy for mCRPC

Darolutamide in mHSPC

LuPSMA moves UpFront

Immunotherapy for prostate cancer

We come in PEACE

Not a Patch on ADT?

Was it a splash or was it a splish?

Radium-223 an option again?

New PSMA-ligand

PSMA-radioligand - the first study of its kind

Metformin in mHSPC

Did CONTACT make any contact?

New PSMA-ligand

PSMA-radioligand - the first study of its kind

Molecular analysis from PEACE-1

IO after IO – is there a role for sequential…

Where is the right place for HIF inhibitors in advanced…

Microbiome transplantation in RCC – how to tailor this…

New SOC for non-cc-RCC?

Updated survival results

Ipi-Nivo in nccRCC

My view on SUNNIFORECAST

FMT in a novel setting

Immunotherapy for nccRCC

CPI - modification / prediction - fact or fantasy?

TKI monotherapy remains standard in 2ndL

Treating nccRCC - Nivo/Ipi as a new potential option

mRCC ≥ 1L? News on intensification?

SUNNIFORECAST - rain or shine?

Sequencing checkpoint inhibitors - the story is over

Glycoproteins as Predictive Biomarkers for Nivolumab…

Stool transplantation is the shit

HIF-2a inhibitors are on their way

IO therapy is standard for nccRCC

The role of sequencing therapy in RCC

Tratamiento del nccRCC - Nivo/Ipi como nueva opción…

Sequencing checkpoint inhibitors - the story is over

Chemo + IO in the perioperative setting - new standard…

Biomarkers in Bladder cancer - the road to…

New standard: perioperative MIBC-NIAGARA

Practice changing new data in Bladder cancer at ESMO24

NIAGARA sets new standard

A new way to give chemo for patients who are ineligible…

New data on ADCs in bladder cancer

Value of ctDNA

TAR200 intravesical +/- Cetrelimab in HR (N)MIBC

mUC - new ADC's?

Pretzel therapy for superficial UC

Nivolumab Plus Gemcitabine-Cisplatin Maintains Quality…

Is intravesical therapy as easy as baking a pretzel?

Nuevos datos sobre las ADC en el cáncer de vejiga

Practice changing new data in Bladder cancer at ESMO24